Big Money Loves Corcept

CORT discovers, develops, and commercializes medications to treat severe metabolic, oncologic, and psychiatric disorders. It focuses on the hormone cortisol, having discovered over 1,000 proprietary cortisol modulators. Its sole marketed drug, Korlym, is an in-demand treatment for Cushing’s syndrome.

In terms of earnings, CORT is expected to show per-share earnings of $1.25 for the fiscal year that ends in December. That would represent a 33% gain from the year prior. In the third-quarter report, the company increased its revenues by 48% from the prior year, to $182.5 million. CORT also upped guidance for this year, eyeing total revenues of $675 million-$700 million (up from $670 million on the top end).

It’s no wonder CORT shares are up 69% this year – and they could rise more. MAPsignals data shows how Big Money investors are betting heavily on the forward picture of the stock.

Corcept Shares Under Accumulation

Institutional volumes reveal plenty. Recently, CORT has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in CORT shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Corcept.

Corcept Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, CORT has had strong sales growth:

• 1-year sales growth rate (+20%)
• 3-year sales growth rate (+11.1%)

Source: FactSet

Also, EPS is estimated to ramp higher this year by +40.6%.

Now it makes sense why the stock has been powering to new heights. CORT has a track record of strong financial performance.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.

Corcept has been a top-rated stock at MAPsignals. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s made the rare Top 20 report multiple times in the last year. The blue bars below show when CORT was a top pick…rising with time:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Corcept Price Prediction

The CORT rally isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author owns positions in CORT in personal and managed accounts at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level, learn more about the MAPsignals process here.